Install
Gene Therapy & Genomic Medicine
CRISPR edits, delivery vectors, rare‑disease trials, and approvals.
- 18 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Gene Therapy & Genomic Medicine
NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results
5+ hour, 34+ min ago (307+ words) ExoPTEN improved retinal responses in injured rat eyes, but the proposed rabbit study still depends on funding and regulatory approvals. NurExone (NRXBF) announced positive preclinical optic nerve injury results supporting plans to advance its program into larger-animal studies. NurExone plans…...
Human cells rejuvenated during reprogramming in Bonn — News-Medical
3+ hour, 50+ min ago (199+ words) UA.NEWS Human cells rejuvenated during reprogramming in Bonn — News-Medical Researchers at Bonn University Hospital and the University of Bonn reprogrammed human erythrocyte precursor cells into neural stem cells and recorded a significant reduction in their molecular age. As News-Medical…...
Genflow Biosciences (GENF) Secures Japanese Patent for SIRT6 Gene Therapy and Expands Animal Health Collaborations
1+ day, 2+ hour ago (17+ words) Kalkine Media...
Scientists Switch On an Embryonic Gene to Rescue a Lethal Blood Disorder
3+ hour, 4+ min ago (868+ words) Bioengineer.org...
Glaukos licenses preclinical tri-specific retinal biologic RO-104 from RevOpsis
13+ hour, 53+ min ago (125+ words) Beyond RO-104, the agreement grants Glaukos exclusive rights to RevOpsis' RevMod platform in geographic atrophy, DME, DR, RVO, and nAMD for the discovery and development of up to four additional retinal biologic candidates, while Glaukos will develop and commercialize RO…...
GenSight's optogenetic gene therapy restores limited visual function in Phase I/II blindness trial
14+ hour, 27+ min ago (323+ words) AllSci is an AI-grounded scientific knowledge platform. It aggregates the global scientific literature, patents, grants and trials, atomizes them into hypotheses, questions, results and claims, links everything to canonical entity identifiers, and answers questions through AERIS with evidence-grounded, sentence-level citations....
RCS - PureTech Health PLC - PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP
8+ hour, 37+ min ago (182+ words) PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress Seaport has initiated a Phase 2a clinical trial evaluating GlyphAgo in adults with generalized anxiety disorder and sleep…...
World’s First Fully Implanted Cochlear Implant Reaches Patients
2+ day, 12+ hour ago (360+ words) Users get round-the-clock hearing with no visible external hardware Edd Gent is a contributing editor for IEEE Spectrum. Med-El’s new cochlear implant places its microphone, sound processor, rechargeable battery, and receiver coil beneath the scalp. “For the first time, all…...
Life Biosciences share glaucoma study updates for its cellular reprogramming drug
9+ hour, 56+ min ago (120+ words) Meghana Keshavan is a biotech correspondent at STAT and co-writer of The Readout newsletter. She joined STAT in 2016. She has written about the life sciences industry for more than a decade. Before that, she worked for news outlets like Thomson…...
Perceive Biotherapeutics Completes Enrollment in Phase 2a JOURNEY Study of VOY-101 Gene Therapy for Geographic Atrophy and Appoints Tony Gibney to Board of Directors
12+ hour, 37+ min ago (103+ words) Oct 09, 2026, 09:00 ET Enrollment in the Phase 2a JOURNEY trial completed - exceeded planned target; topline 15-month data expected in late 2027 Phase 2a enrollment complete, exceeding planned target Industry veteran Tony Gibney joins the Company's Board of Directors About VOY-101 and the JOURNEY Study…...